Avenue Therapeutics, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Note 1 - Organization, Plan of Business Operations (Details Textual)

Note 1 - Organization, Plan of Business Operations (Details Textual)									1 Months Ended	12 Months Ended
	Nov. 05, 2025 USD ($)	Apr. 24, 2025 USD ($)	May 10, 2024 USD ($) $ / shares	May 01, 2024 USD ($)	Apr. 25, 2024	Jan. 05, 2024 USD ($) $ / shares shares	Feb. 28, 2023 USD ($)	Sep. 30, 2016 shares	Oct. 31, 2022 USD ($) shares	Dec. 31, 2025 USD ($) $ / shares shares	Dec. 31, 2024 USD ($) $ / shares	May 31, 2024 USD ($)	Apr. 28, 2024 $ / shares shares	Jan. 31, 2024 USD ($)	Dec. 31, 2023 $ / shares	Nov. 30, 2023 $ / shares shares	Jan. 31, 2023 $ / shares shares	May 11, 2022
Deconsolidation, Gain (Loss), Amount										$ 203,000	$ (0)
Stockholders' Equity Note, Stock Split, Conversion Ratio											75
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares										$ 10.56	$ 8.64				$ 32.42
Fair Value Adjustment of Warrants										$ (15,000)	$ (170,000)
Proceeds from Warrant Exercises										$ 0	$ 9,421,000
Common Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares			$ 0.0001							$ 0.0001	$ 0.0001
Stock Issued During Period, Shares, New Issues (in shares) \| shares								250,000
Proceeds from Issuance of Common Stock										$ 2,094,000	$ 1,623,000
Retained Earnings (Accumulated Deficit)										$ (105,489,000)	(102,580,000)
ATM Agreement [Member]
Offering Agreement, Maximum Amount			$ 3,850,000
Commission Fee, Percent Fee			3.00%
Stock Issued During Period, Shares, New Issues (in shares) \| shares										938,990
January 2023 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares																	25,871
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares						$ 22.545									$ 116.25		$ 116.25
Fair Value Adjustment of Warrants						$ 100,000
November 2023 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares													221,333			194,667
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares						$ 22.545							$ 22.545			$ 22.545
New Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares						220,538
Warrants and Rights Outstanding, Term (Year)						5 years
Warrants and Rights Issued Classified as Deemed Dividend						$ 600,000
New Series B Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares						220,538
Warrants and Rights Issued Classified as Deemed Dividend						$ 4,300,000
Existing Warrants [Member]
Proceeds from Warrant Exercises						$ 4,500,000
October 2022 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares													27,271
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares													$ 116.25
Fair Value Adjustment of Warrants				$ 100,000
January 2024 Warrant Inducement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares													441,076
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares													$ 22.545
Warrants and Rights Issued Classified as Deemed Dividend														$ 4,300,000
May 2024 Warrant Inducement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares													6.2
Fair Value Adjustment of Warrants				200,000
Warrants and Rights Issued Classified as Deemed Dividend				4,500,000								$ 4,500,000
Proceeds from Warrant Exercises				$ 3,700,000
Warrant Payment, Price Per Share (in dollars per share) \| $ / shares													$ 0.125
New Class C Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares													689,680
New Class D Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares													689,680
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio					75
Baergic [Member]
Sale of Nonfinancial Assets, Contingent Consideration, Range of Outcomes, Maximum, Percentage	74.00%
Sale of Nonfinancial Assets, Upfront Fee Received	$ 300,000
Sale of Nonfinacial Assets, Transaction Costs	$ 100,000
Deconsolidation, Gain (Loss), Amount										$ 200,000
Baergic [Member] \| Axsome [Member]
Business Combination, Voting Equity Interest Acquired, Percentage	100.00%
Business Combination, Consideration Transferred	$ 300,000
Baergic [Member] \| Axsome [Member] \| Occurrence of Certain Development and Regulatory Milestones [Member]
Business Combination, Contingent Consideration, Range of Outcomes, Maximum, Amount	2,500,000
Baergic [Member] \| Axsome [Member] \| Each Indicator After [Member]
Business Combination, Contingent Consideration, Range of Outcomes, Maximum, Amount	1,500,000
Baergic [Member] \| Axsome [Member] \| AXS-17 Achieving Certain Commercial Sales Milestone [Member]
Business Combination, Contingent Consideration, Range of Outcomes, Maximum, Amount	$ 79,000,000
Invagen Pharmaceuticals Inc [Member]
Business Combination, Contingent Consideration, Range of Outcomes, Maximum, Amount									$ 4,000,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) \| shares									5,185
Sale of Stock, Cash Transaction Fees, Percentage of Gross Cash Proceeds									7.50%
Payments for Stock Purchase Costs										200,000	$ 700,000
Payment of Contingent Fee										$ 1,400,000
Fortress [Member] \| Contribution Agreement [Member]
Percentage of Transfer Ownership																		100.00%
AnnJi [Member]
License Agreement, Purchase Consideration							$ 3,000,000
Maximum Reimbursement Amount In Connection With Product Clinical Trial							10,800,000
Maximum Reimbursement Amount In Connection With Certain Development Milestones							14,500,000
Maximum Reimbursement Amount In Connection With Certain Drug Development Milestone							27,500,000
Maximum Reimbursement Amount Upon Achievement of Sales Milestone							165,000,000
Payments for Repurchase of Common Stock		$ 1
Payments Upon Termination of Agreement		200,000
Termination Payments Receivable		$ 1,600,000
License Agreement, Tax Withholding, Percent		20.00%
Termination Payments Receivable Within Thirty Days		$ 800,000
Termination Payments Receivable Within Ninety Days		800,000
Eligible Termination Payments, Development and Regulatory Milestones		5,000,000
Eligible Termination Payments, Commercial Sales Milestones		$ 17,000,000
Eligible Termination Payments, Royalty Percentage on Net Sales		1.75%
Eligible Termination Payments, Percentage of Subsequent Licensees		15.00%
AnnJi [Member] \| Minimum [Member]
Sales Milestone Required for Maximum Reimbursement							75,000,000
Eligible Termination Payments, Subsequent Licensees		$ 4,000,000
AnnJi [Member] \| Maximum [Member]
Sales Milestone Required for Maximum Reimbursement							$ 750,000,000
Eligible Termination Payments, Subsequent Licensees		$ 7,500,000